Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Frans L. Opdam"'
Autor:
Birgit S. Geurts, Thomas W. Battaglia, J. Maxime van Berge Henegouwen, Laurien J. Zeverijn, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Frans L. Opdam, Maja J. A. de Jonge, Geert A. Cirkel, Mariette Labots, Ann Hoeben, Emile D. Kerver, Adriaan D. Bins, Frans G.L. Erdkamp, Johan M. van Rooijen, Danny Houtsma, Mathijs P. Hendriks, Jan-Willem B. de Groot, Henk M. W. Verheul, Hans Gelderblom, Emile E. Voest
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP
Externí odkaz:
https://doaj.org/article/0e6af27c660548eab8d0d86d81fe251d
Autor:
Tim Schutte, Laurien J Zeverijn, Birgit S Geurts, Gijsbrecht F de Wit, Marleen Kok, Frans L Opdam
Publikováno v:
The Oncologist.
Alpelisib is a specific oral PI3K inhibitor used combined with fulvestrant for the treatment of patients with HR+/HER2–/PIK3CA-mutated metastatic breast cancer. Adverse drug reactions with alpelisib are common, including hyperglycemia and rash. Her
Autor:
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurelien Marabelle, Jeffrey S Weber, John V Heymach
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005301
BackgroundThe phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.MethodsGSK317
Autor:
Frans L. Opdam, Robin M. J. M. van Geel, Neeltje Steeghs, Emilie M.J. van Brummelen, Alwin D. R. Huitema, Serena Marchetti, Jos H. Beijnen, Jan H.M. Schellens, Sanne Huijberts, Hilde Rosing, Kim Monkhorst, Saskia M. Pulleman, Bas Thijssen, René Bernards
Publikováno v:
Cancer Chemotherapy and Pharmacology, 85(5), 917-930. Springer Verlag
Purpose KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo.
Autor:
Fabien Calvo, David Tamborero, Elena Chavarria, Rodrigo Dienstmann, Emile E. Voest, Carlos Caldas, Claudio Vernieri, Janne Lehtiö, Giovanni Apolone, Xenia Villalobos, Ingemar Ernberg, Christophe Massard, Jeffrey Yachnin, Stefan Fröhling, Michele Masucci, Alexander M.M. Eggermont, Frans L. Opdam, Richard D. Baird, Josep Tabernero, Luigi De Petris, Maan Haj Rachid, Richard F. Schlenk, Jordi Rodon, Irene Brana, Elena Garralda, Jorrit Boekel
Publikováno v:
Nature Medicine. 26:992-994
Autor:
Jonas Bergh, Janne Lehtiö, Emile E. Voest, David Tamborero, Jordi Rodon, Elena Garralda, Irene Brana, Jeffrey Yachnin, Carlos Caldas, Claudio Vernieri, Richard D. Baird, Judith Balmaña, Ingemar Ernberg, Richard F. Schlenk, Giovanni Apolone, Stefan Fröhling, Maan Haj Rachid, Claes Karlsson, Jorrit Boekel, Elena Chavarria, Christophe Massard, Xenia Villalobos, R. Dienstmann, Luigi De Petris, Michele Masucci, Adrià López-Fernández, Frans L. Opdam, Josep Tabernero
There is a growing need for systems that efficiently support the work of medical teams at the precision oncology point-of-care. Here we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6675885b197f2826eef743c30ca9d61
https://doi.org/10.21203/rs.3.rs-401975/v1
https://doi.org/10.21203/rs.3.rs-401975/v1
Autor:
David, Tamborero, Rodrigo, Dienstmann, Maan Haj, Rachid, Jorrit, Boekel, Richard, Baird, Irene, Braña, Luigi, De Petris, Jeffrey, Yachnin, Christophe, Massard, Frans L, Opdam, Richard, Schlenk, Claudio, Vernieri, Elena, Garralda, Michele, Masucci, Xenia, Villalobos, Elena, Chavarria, Fabien, Calvo, Stefan, Fröhling, Alexander, Eggermont, Giovanni, Apolone, Emile E, Voest, Carlos, Caldas, Josep, Tabernero, Ingemar, Ernberg, Jordi, Rodon, Julia, Wolfart
Publikováno v:
Nature medicine. 26(7)
Autor:
Filip De Vos, Ferry A.L.M. Eskens, Martijn P. Lolkema, Bas Thijssen, Robin van Geel, Neeltje Steeghs, Emilie M.J. van Brummelen, Serena Marchetti, Lot A. Devriese, René Bernards, Frans L. Opdam, Alwin D. R. Huitema, Hilde Rosing, Jan H.M. Schellens, Kim Monkhorst, Jos H. Beijnen, Sanne Huijberts
Publikováno v:
British Journal of Cancer, 122(8), 1166. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 122(8), 1166-1174. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 122(8), 1166-1174. Nature Publishing Group
Background Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS-mutant tumours existing treatment options, e.g. MEK inhibition, have limited efficacy due to resistance through feedback activation of epidermal growth factor rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93b187e3733cbb74ac196b6f9e85915e
https://dspace.library.uu.nl/handle/1874/411157
https://dspace.library.uu.nl/handle/1874/411157
Autor:
Maria Vieito Villar, Courtney Henry, Sapna Yadavilli, Victor Moreno, Antoine Italiano, Omid Hamid, Marc S. Ballas, Marco Balas, Michael Chisamore, Frans L. Opdam, Michele Maio, Xiao Ji, Jeffrey S. Weber, Axel Hoos, David C. Turner, Jose Manuel Trigo, Catherine E. Ellis
Publikováno v:
Cancer Research. 81:CT033-CT033
Background: INDUCE-1 is a first-in-human trial investigating FE, an IgG4 ICOS agonist non-T-cell depleting mAb, in monotherapy (mono) and combo with PD-1 inhibitor PE. ICOS is highly expressed in melanoma, an immunotherapy responsive tumor, and is a
Autor:
Harm C. den Boer, Farshid Alemdehy, Bryony J. Telford, Debbie Robbrecht, Nuria Kotecki, Laurens Adrianus Hendricus Van Pinxteren, Sanaz Yahyanejad, Marion T.J. van den Bosch, Karlijn Kroon, Frans L. Opdam, Thijs de Gunst, Rogier M. Vos, Michiel Strijbos, Michel Janicot, Roel Q.J. Schaapveld
Publikováno v:
Journal of Clinical Oncology. 39:TPS2666-TPS2666
TPS2666 Background: MicroRNAs (miR) are naturally-occurring small non-coding RNA molecules involved in the regulation of gene expression and their dysregulation plays a fundamental role in several pathological conditions including cancer. The miR-193